Research Conference Poster Index

Plan your conference by viewing the poster presentation sessions at this year's Research Conference

Item text
P1 Development of an immunoassay based device for measuring cortisol as a marker of stress in patients with neurodegenerative conditions
Katherine Deane, University of East Anglia
P4 Investigating the biomarker potential of post-translationally modified α-synuclein in cerebral spinal fluid
Craig Leighton, University of Edinburgh
P7 Monitoring Parkinson's using smartphones and behavioural inferences
Julio Vega, University of Manchester
P10 Moving to the music, not the beat: embodied sensorimotor entrainment in Parkinson's
Dawn Rose, University of Hertfordshire
P13 Multimorbidity predicts quality of life but not motor severity in early Parkinson's
Rachael Lawson, Institute of Neuroscience, Newcastle University
P16 Pierre D – the story behind one of the most prominent images in Parkinson's
Patrick Lewis, University of Reading
P19 Newcastle-upon-Tyne deep brain stimulation rehabilitation project
Heather Hunter, Newcastle-upon-Tyne Hospitals NHS Foundation Trust
P22 Developing a multi-arm, multi-stage (MAMS) trial platform in Parkinson's
Thea Dominey, Plymouth University Peninsula Schools of Medicine and Dentistry

Evidence for altered top-down processing of pain in Parkinson's
Sarah Martin, The University of Manchester

P28 Difficulty desynchronising beta activity underlies memory deficits in Parkinson's
Hayley MacDonald, University of Birmingham
P31 The Parkinson's linked protein DJ-1 associates with cytoplasmic mRNP granules during stress and neurodegeneration
Mariaelena Repici, University of Leicester
P34 Changes in muscle activity on application of an auditory rhythmic cue
Aisha Islam, Newcastle University
P37 Study of α-synuclein aggregates toxicity with a nanopipette delivery system
Chalmers Chi Cheng Chau, University of Leeds
P40 AKT signalling selectively regulates PINK1 mitophagy in SHSY5Y cells and human iPSC-derived neurons
Marc Soutar, UCL
P43 Single cell transcriptomic dynamics of human dopamine neurons
Hugo Fernandes, Dementia Research Institute, Cambridge
P46 Exploring the pathogenic role of dRab39 in a Drosophila model of Parkinson's
Charlotte Smith, University of Leicester
P49 Down-regulation of MMP2 and TGFB1 in Parkinson's LRRK2 G2019S iPSC-derived astrocytes
Frank Wessely, Dementia Research Institute, Cardiff University
P52 A model system for uptake and aggregation of pre-formed fibrillar α-synuclein in iPSC-derived dopamine neurons
Siv Vingill, University of Oxford
P55 Tonic GABA inhibition of striatal dopamine transmission is regulated by GABA transporter activity and augmented in parkinsonian mice
Bradley Roberts, University of Oxford
P58 Strategies to regenerate the nigrostriatal pathway in an organotypic rat model of Parkinson's
Timothy Goodman, Keele University
P61 Mass-spectrometry approach highlights REST as a potential neuroprotective target for Parkinson's in an alpha synuclein overexpressing BAC-transgenic mouse model
Nora Bengoa-Vergniory, OPDC
P64 Regulation of basal mitophagy and pexophagy by the mitochondrial deubiquitylase USP30
Jane Jardine, University of Liverpool
P67 Human-specific levels of CDNF, MANF and ER stress in the pathological progression of Parkinson's
Ilaria Poggiolini, Nuffield Department of Clinical Neuroscience, Oxford Parkinson’s Disease Centre
P70 Development of a home-based therapy to improve functional actions in people with Parkinson's using observation and imagery
Ellen Poliakoff, University of Manchester
P73 Exploring the roles of vitamins in the differentiation and protection of dopamine neurons
Emma Green, Keele University
P76 How patient and public involvement shaped the development of a training tool for impulse control disorders in Parkinson's
Jade Pickering, University of Manchester
P79 How do people with Parkinson's respond to expression and meaning in dance?
Judith Bek, University of Manchester
P82 The effect of aerobic exercise on cognition in people with Parkinson's: a modified systematic review
Grace Chillingworth, RJAH Orthopaedic Hospital NHS FT, Oswestry
P85 Manual to automated process transfer of pluripotent cell expansion and differentiation for the production of dopaminergic neurons as a cell therapy for Parkinson's
Preeti Holland, Loughborough University
P88 Wrist-worn accelerometer measures of activity by people with Parkinson's during and in the week following participation in a dance class
Rebecca Hadley, University of Hertfordshire
Item text
P5 Automated measures from neuromelanin-sensitive MRI reveal signs of neurodegeneration in rapid eye movement sleep behaviour disorder
Ludovica Griffanti, University of Oxford
P8 Co-creation of guidance and quality criteria for patient engagement in the development of clinical interventions: an international multi-stakeholder initiative
Katherine Deane, University of East Anglia (on behalf of the Patient Focused Medicines Development Coalition)
P11 Pro-saccades predict cognitive decline in Parkinson's
Rachael Lawson, Newcastle University
P14 Frailty status predicts falls in early Parkinson's
Alison Yarnall, Institute of Neuroscience, Newcastle University
P17 Smartphone prediction of clinical motor scores and future falls, freezing and disability in the Oxford Discovery cohort
Christine Lo, University of Oxford
P20 A multi-centre randomised controlled trial to compare the linical and cost effectiveness of Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson’s (PD COMM)
Max Hughes, University of Birmingham
P23 Structural neural correlates of independent gait characteristics in Parkinson’s
Joanna Wilson, Institute of Neuroscience, Newcastle University

Interaction of LRRK2 with Rab GTPases in vivo
Chris Elliott, University of York

P29 p27Kip1regulates alpha-synuclein expression
Edurne Gallastegui, University of Barcelona, Barcelona, Spain
P32 Anxiety in Parkinson's: the role of the locus coeruleus-stress circuitry
Mohsen Seifi, University of Portsmouth
P35 Integrated systems approach to identify genetic networks and hubs in Parkinson's
Jack Kelly, University of Plymouth
P38 Mitochondrial deficiencies in LRRK2-G2019S Parkinson's
Ruby Macdonald, Sheffield Institute for Translational Neuroscience, University of Sheffield
P41 Endosomal trafficking dysfunction in Parkinson's
Kirsty McMillan, University of Bristol
P44 Transcriptomic analysis of induced pluripotent stem cell derived dopaminergic neurons from patients with sporadic Parkinson's
Jimena Monzón Sandoval, Cardiff University
P47 Investigating low-level single nucleotide mosaicism in sporadic Parkinson's
Melissa Leija-Salazar, University College London
P50 Early Synaptic changes in the CRISPR-engineered G51D αSynuclein rat
Stephen West, Centre for Regenerative Medicine, University of Edinburgh
P53 Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene
Yixi Chen, MRC Centre for Regenerative Medicine, University of Edinburgh
P56 Mitochondrial abnormalities in parkin mutant patient derived dopaminergic neurons are driven by the metabolic status of the neuron
Aurelie Schwartzentruber, Sheffield Institute for Translational Neuroscience
P59 Dopamine pre and post-synaptic signalling in a LRRK2 transgenic rodent model of Parkinson's using 18F-Levodpa and 18F-Fallypride PET imaging
Teresa Delgado-Goni, Oxford Parkinson's Disease Centre
P62 Alterations in mitochondrial function and network in iAstrocytes derived from parkin mutant patients
Heather Mortiboys, University of Sheffield
P65 Three-dimensional and stereological characterisation of the Human Pedunculopontine nucleus during Parkinson's
Ilse Pienaar, University of Sussex
P68 Alginate hydrogels to encapsulate hiPSC-derived neurons for Parkinson's
Rachael Evans, Department of Pharmacology, UCL School of Pharmacy
P71 A novel role for SENP3 in iron chelation-induced mitophagy for the treatment of Parkinson's
Emily Waters, University of Sheffield
P74 Do gabapentinoid drugs have neuroprotective or therapeutic potential for the treatment of Parkinson's?
Katherine Brimblecombe, University of Oxford
P77 Assessing the effect of small molecule glucocerebrosidase modulators on GBA-associated phenotypes in iPSC-derived dopaminergic neuronal cultures
Uroosa Chughtai, Oxford Parkinson's Disease Centre
P80 A co-developed dance programme for Parkinson's: pilot testing and potential outcomes
Aline Arakaki, University of Manchester
P83 Human action influences hand movements more than simple cues in Parkinson's
Judith Bek, University of Manchester
P86 Suppression of Caspases and NFκB classical pathway enhanced survival of stressed dopaminergic neurons
Bushra Ahmed, University of Bedfordshire
P89 Translational requirements for manufactured dopaminergic neurons for the treatment of Parkinson's
James Kusena, Centre for Biological Engineering, Loughborough University
Item text
P3 Reduced habit-driven errors in Parkinson's
Colin Bannard, University of Liverpool
P6 Patient experiences of receiving a diagnosis of Parkinson's
S Modi, Department of Clinical Neurosciences, UCL Institute of Neurology
P9 Use of iPad-based pre-assessment questionnaires in Parkinson's clinics: a qualitative study of patients' perceptions
Amani Khardali, School of Pharmacy and Pharmaceutical Sciences, Cardiff University
P12 The Evidence Based Practice Committee and the UK Parkinson’s Excellence Network
Alison Yarnall, Institute of Neuroscience, Newcastle University
P15 Is dual task walking associated with cognitive impairment in Parkinson's?
Laura Stuart, Institute of Neuroscience
P18 Show me the way: gesturing about space in Parkinson's
Ellen Poliakoff, University of Manchester
P21 Top 10 research priorities for the management of Parkinson's. An international cross-sectional survey in the frame of the CENTRE-PD project
Francesca Bowring, Oxford University/UCL
P24 Prefrontal cortical activity decreases in people with Parkinson's when performing a cognitively challenging walking task compared to usual walking
Annette Pantall, Newcastle University

Human-specific transcriptomic profiling of ventral and dorsal midbrain dopamine neurons
Laura Parkkinen, Nuffield Department of Clinical Neurosciences, Oxford Parkinson's Disease Centre

P30 Cell signalling in live brains, neurones and immune cells in LRRK2 Parkinson's disease models
Kirsten Harvey, University College London
P33 Exploiting cellular heterogeneity through single cell sequencing reveals HDAC4 as a regulator of cellular phenotypes in Parkinson's dopamine neurons
Charmaine Lang, University of Oxford
P36 A quantitative proteomics assessment of the substantia nigra revealed dysregulation of glial proteins in aged rats: implications for idiopathic Parkinson's
Yolanda Gómez-Gálvez, Institute for Science and Technology in Medicine (Keele University)
P39 Apathy in rapid eye movement sleep behaviour disorder is associated with serotonin depletion in the dorsal raphe nucleus
Thomas Barber, University of Oxford
P42 High content screening to identify modulators of mitophagy in neurodegenerative disease
Daniela Melandri, University College London
P45 Somatic copy number gains of the alpha-synuclein gene in synucleinopathies
Christos Proukakis, UCL Institute of Neurology
P48 Prioritisation of GWAS genes in Parkinson's associated loci through interaction networks identifies dopaminergic-specific genes showing functional and genetic convergence in independent datasets
Viola Volpato, Cardiff University
P51 Linking Leucine rich repeat kinase 2 (LRRK2) – Parkinson's and inflammation
Rina Bandopadhyay, Reta Lila Weston Institute, UCL Institute of Neurology
P54 Depicting mitochondrial function and mitophagy in Parkinson's patient iPSC-derived dopaminergic neurons
Marta Cherubini, Oxford Parkinson’s Disease Centre and Department of Physiology, University of Oxford
P57 Insights into the role of LRRK2 in the endocytic pathway and identification of novel LRRK2 substrates
Natalie Connor-Robson, University of Oxford
P60 Does dysregulation of calcium homeostasis converge with maturing neurotransmission to cause long-term energy deficit in GBA iPSC derived neurons?
Dayne Beccano-Kelly, University of Oxford
P63 Astrocytes in Parkinson's
Lucy Crompton, University of Bristol
P66 The observed association between dementia with Lewy bodies, APOE-ɛ4 and TOMM40 Poly-T repeat long allele variants is due to co-existing Alzheimer's pathology
Clara Erixon, Department of Medical and Health Sciences, Linkoping University, Linkoping, Sweden
P69 The effectiveness of peroneal nerve functional electrical STimulation (FES) for the reduction of bradykinesia in Parkinson's: a pragmatic feasibility study for an assessor-blinded randomised control trial (STEPS)
Paul Taylor, Salisbury NHS Foundation Trust
P72 Non-invasive vagus nerve stimulation: a non-pharmacological approach to target gait impairment in Parkinson's?
Alison Yarnall, Institute of Neuroscience, Newcastle University
P75 Tools to monitor the production of a midbrain dopaminergic precursor cell product
Nicola Drummond, The University of Edinburgh
P78 A targeted repurposing approach to find Food and Drug Administration (FDA) approved drugs that boost endogenous fibroblast growth factor 20 for use in future neuroprotective studies
Edward Fletcher, King's College London
P81 Phenotypic drug discovery in iPSC-derived dopaminergic neuronal cultures
Janine Brandes, University of Oxford
P84 Screening of novel modified steroids for mitochondrial rescue effect in Parkinson's
Christopher Hastings, University of Sheffield
P87 Mitochondrial high content image screening in Parkinson's patient tissue
Heather Mortiboys, University of Sheffield
P90 Identifying novel drugs and targets through integrating phenotypic screening data across Parkinson's models
Brent Ryan, OPDC, University of Oxford

Latest information

All announcements on the conference will be made via our e-newsletter Synapse.

For any questions please contact: